15th Annual BIO CEO & Investor Conference to Highlight Drivers of Biotech Momentum
WASHINGTON, D.C. (November 27, 2012) – Now in its fifteenth year, the BIO CEO & Investor Conference, hosted by the Biotechnology Industry Organization(BIO), is the largest independent investor conference focused on publicly-traded biotechnology companies. Held in New York City, February 11 – 12, 2013, the event will feature issue-oriented plenary sessions, educational sessions focused on timely therapeutic areas and key business issues, company presentations, one-on-one meetings and networking opportunities.
The conference focuses on public market biotech companies, which are having a banner year, substantially outperforming the broader market indices. The Nasdaq Biotech Index (NBI) is up 27% year-to-date, beating the S&P 500 by a factor of 3. The sector’s climb has been driven by late-stage pipelines with impressive data and blockbuster potential, as well as positive trial data in orphan disease indications and over 30 innovative drug approvals so far this year.
“In addition to the sector’s overall public market performance, this year’s IPOs have had strong, positive performance similar to the index, giving private companies hope for successful market debuts. That, plus a return of pre-clinical IPOs and the passage of the JOBS Act indicate that the IPO window may be opening a bit wider than in recent years,” stated Alan Eisenberg, Executive Vice President, Emerging Companies and Business Development. This year, the conference will feature a new track of company presentations from late-stage private companies to better showcase the growth opportunities in this area of the industry. “Investors are increasingly finding value in pre-IPO companies, through crossover investing and other investment vehicles,” added Eisenberg.
“Many of the companies that fueled the tremendous performance of the NBI will be presenting at BIO CEO. This event is the first major East Coast biotech event for 2013, and is an invaluable opportunity for industry executives, as well as sector-specific and generalist investors,” added Eisenberg.
The robust conference program will also include Fireside Chats with industry leaders, Therapeutic Workshops focused on the latest pipeline innovations and breakthrough therapies, and Business Roundtables centered on examining investment and deal-making trends with seasoned industry executives and analysts. Additionally, the conference features presentations from over 130 publicly-traded biotechnology and pharmaceutical companies.
One-on-one meetings at this conference will be powered by BIO One-on-One Partnering™, an interactive environment to intelligently search, contact and schedule private meetings with potential partners and investors. Event attendees will have the opportunity to arrange meetings between investors, companies and industry executives. This industry-specific, web-based interactive software enables participants to move efficiently from the identification of prospective partners to discussion and negotiations.
Registration for the event is now open. Qualified institutional and venture investors whose primary activity is direct investment in research and development companies are eligible for complimentary registration. Equity research analysts from investment banking institutions also qualify as investors. Media registration also is complimentary for credentialed members of the media. All registrations are subject to verification of credentials.
BIO Industry Analysis offers the biotech industry market data to helpguide decision making within the industry. The BIO Industry Analysis blog can be found here, and you can subscribe to future email newsletters here.
BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors including supporting banks Stifel Nicolaus Weisel, Leerink Swann and ROTH Capital Partners, LLC.